期刊文献+

不同剂量辛伐他汀对急性冠状动脉综合征患者组织因子和组织因子途径抑制物的影响 被引量:11

Effects of Different Doses of Simvastatin on Plasma Levels of Tissue Factor and Tissue Factor Pathway Inhibitor in Patients with Acute Coronary Syndromes
下载PDF
导出
摘要 目的观察不同剂量的辛伐他汀对急性冠状动脉综合征患者血浆组织因子和组织因子途径抑制物的影响。方法将88例急性冠状动脉综合征患者分为对照组28例、辛伐他汀20 mg组29例和辛伐他汀40 mg组31例,在入院第2天和在平均治疗8天以后清晨空腹采血,用酶联免疫吸附法测定血浆中的组织因子活性和组织因子途径抑制物的水平。结果辛伐他汀治疗的两个组组织因子活性较治疗前明显降低,分别从0.47±0.58 IU/L下降到0.20±0.30 IU/L和从0.59±0.77 IU/L下降到0.36±0.55 IU/L(P<0.05),对照组组织因子活性无变化;辛伐他汀40 mg组组织因子途径抑制物的水平增高,从263±203μg/L增加到369±279μg/L(P<0.05),但其他两组组织因子途径抑制物水平在治疗前后无差异。结论20 mg和40 mg辛伐他汀短期治疗急性冠状动脉综合征患者均能使组织因子活性降低,40 mg辛伐他汀治疗时使组织因子途径抑制物水平增高,提示他汀对组织因子和组织因子途径抑制物的作用可能是其抗栓机理之一。 Aim To investigate the effects of different doses of simvastatin on plasma activity of tissue factor(TF) and level of tissue factor pathway inhibitor(TFPI) in patients with acute coronary syndromes(ACS). Methods A total of 88 patients with acute coronary syndromes were randomized in to three groups: control group without use of statin, group with 20 mg and group with 40 mg simvastafin therapy. The plasma activity of TF and level of TFPI were measured using IMUBIND^R enzymelinked immunosorbent assay ( ELISA ) kit. Results Both doses of simvastatin therapy can significantly decrease the activity of TF ( from 0.47 ± 0.58 IU/L to 0.20 ± 0.30 IU/L and from 0.59 ± 0.77 IU/L to 0.36 ± 0.55 IU/L, respectively) ( P 〈 0.05 ), only large dose of simvastatin (40 mg group) can increase TFPI level (from 263 ± 203 μg/L to 369 ± 279 μg/L) ( P 〈 0.05). Conclusions Simvastatin can change plasma activity of TF and level of TFPI and may have antithrombotie effect.
出处 《中国动脉硬化杂志》 CAS CSCD 2005年第5期633-635,共3页 Chinese Journal of Arteriosclerosis
关键词 内科学 酶联免疫吸附法 急性冠状动脉综合征 组织因子 组织因子途径抑制物 他汀类 辛伐他汀 Enzyme-Linked Immunosorbent Assay Acute Coronary Syndromes Tissue Factor Tissue Factor Pathway Inhibitor HMG-COA Reduetase Inhibltors Statins Simvastatin
  • 引文网络
  • 相关文献

参考文献13

  • 1Golino P, Ravera A, Ragni M, Cirillo P, Piro O, Chiariello M. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation, 2003, 108: 2 684-689.
  • 2Tsiara S, Elisaf M, Michailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin, 2003, 19: 540-556.
  • 3黄全跃,赵水平.他汀类药物的抗血栓作用[J].医学临床研究,2004,21(1):12-14. 被引量:35
  • 4Kaikita ML, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K, et al. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol, 1999, 103: 879-887.
  • 5Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J, 1997, 134: 253-259.
  • 6Son JW, Koh KK, Ahn JY, Jin DK, Kin HS, Choi YM, et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol, 2003, 88(1): 77-82.
  • 7Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Improved fobrinolysis after 1-year treatment with HMG-CoA reductase inhibitors in patients with coronary disease. Thromb Res, 2002, 105: 285-290.
  • 8Morange PE, Simon C, Alessi MC, Luc G, Arvetler D, Ferrieres J. Endothelial cell markers and the risk of coronary heart disease. The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Circulation, 2004, 109: 1 343-348.
  • 9Maly M, Vojacek J, Hrabos V, Kvasnicka J, Salaj P, Durdil V. Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndromes. Physiol Res, 2003, 52: 719-728.
  • 10Sandest PM, Lund H, Norseth J, Abildgaard U, Ose L. Treament with hydroxymethylglutaryl-Coenzyme A reductase inhibitori in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb, 1991, 11: 138-145.

二级参考文献25

  • 1Bonetti PO,Lerman LO,Napoli C,el a1.Statin effects beyond lipid lowering:are they clinically relevant[J]?Euro Heart J,2003,24:225-248.
  • 2Laufs U,Gertz K,Huang P,et al.Atorvastatin upregulates type Ⅲ nitric oxide synthase in thrombocytes,decreases platelet activation,and protects from cerebral ischemia in normocholesterolemic mice[J].Stroke,2000,31(10):2442-249.
  • 3Gertz K,Laufs U,Lindauer U,et al.Withdrawal of statin treatment abrogates stroke protection in mice[J].Stroke,2003,34:551-557.
  • 4Eto M,Kozai T,Cosentino F,et al.Statin prevents tissue factor expression in human endothelial cells:role of Rho/Rho-kinase and Akt pathways[J].Circulation,2002,105:1756-1759.
  • 5Rosenson RS.Brown AS.Statin use in acute coronary syndromes:cellular mechanism and clinical evidence[J].Curr Opin Lipidol,2002,13:625—630.
  • 6Son JW.Koh KK.Ahn JY,et al.Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease[J].Int J Cardiol,2003,88(1):77—82.
  • 7Undas A, Brummel KE, Musial J, et al . Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V ,and factor Ⅻ and by enhancing factor V a inactivation[J]. Grculation ,2001,103(18) :2248-2253.
  • 8Musial J, Undas A, Undas R, et al . Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels[J]. Thromb Haemost , 2001,85 : 221-225.
  • 9Morishita E, Minami S,Ishino C, et al . Atorvastatin reduces plasma levels of factor Ⅶ activity and factor Ⅶ antigen in patients with hyperlipidemia[J]. J Atheroscler Thromb , 2002,9:72-77.
  • 10Olivotti L, Ghiglitti G, Spallarossa P, et al . High dose of atorvastatin do not affect activity of prothrombinases with acute coronary syndromes[J]. Blood Coagul Fibrinolysis ,2002,13:315-322.

共引文献42

同被引文献92

引证文献11

二级引证文献49

相关主题

;
使用帮助 返回顶部